Literature DB >> 12847667

Understanding the window of opportunity concept in early rheumatoid arthritis.

Maarten Boers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847667     DOI: 10.1002/art.11156

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  42 in total

Review 1.  [Early diagnosis of rheumatoid arthritis].

Authors:  M Schneider; B Ostendorf; C H Specker
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 2.  Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications.

Authors:  Francisco Espinoza; Sylvie Fabre; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-13       Impact factor: 5.346

3.  Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.

Authors:  Carol A Wallace; Edward H Giannini; Steven J Spalding; Philip J Hashkes; Kathleen M O'Neil; Andrew S Zeft; Ilona S Szer; Sarah Ringold; Hermine I Brunner; Laura E Schanberg; Robert P Sundel; Diana Milojevic; Marilynn G Punaro; Peter Chira; Beth S Gottlieb; Gloria C Higgins; Norman T Ilowite; Yukiko Kimura; Stephanie Hamilton; Anne Johnson; Bin Huang; Daniel J Lovell
Journal:  Arthritis Rheum       Date:  2011-12-19

4.  High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study.

Authors:  Hilal Maradit Kremers; Cynthia S Crowson; Terry M Therneau; Veronique L Roger; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2008-08

5.  Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis?

Authors:  James Woodburn; Kym Hennessy; Martijn Pm Steultjens; Iain B McInnes; Deborah E Turner
Journal:  J Foot Ankle Res       Date:  2010-05-17       Impact factor: 2.303

6.  Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; D Isenberg; A Rahman; G S Alarcón; D D Gladman; P R Fortin; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; E Ginzler; I N Bruce; K Steinsson; M Khamashta; M Petri; S Manzi; M A Dooley; R Ramsey-Goldman; R Van Vollenhoven; O Nived; G Sturfelt; C Aranow; K Kalunian; M Ramos-Casals; A Zoma; J Douglas; K Thompson; V Farewell
Journal:  Ann Rheum Dis       Date:  2009-04-08       Impact factor: 19.103

7.  Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

Authors:  Marion A J van Rossum; Renée M van Soesbergen; Maarten Boers; Aeilko H Zwinderman; Theo J W Fiselier; Marcel J A M Franssen; Rebecca ten Cate; Lisette W A van Suijlekom-Smit; Nico M Wulffraat; Wilma H J van Luijk; Johanna C M Oostveen; Wietse Kuis; Ben A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

8.  Influence of patient personality in the treatment of rheumatoid arthritis.

Authors:  Leticia Leon; Marta Redondo; Alberto Garcia-Vadillo; Miguel A Perez-Nieto; Luis Rodriguez-Rodriguez; Juan A Jover; Isidoro Gonzalez-Alvaro; Lydia Abasolo
Journal:  Rheumatol Int       Date:  2016-09-10       Impact factor: 2.631

9.  Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort.

Authors:  Maria D Mjaavatten; Till Uhlig; Anne J Haugen; Halvor Nygaard; Göran Sidenvall; Knut Helgetveit; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2009-10-01       Impact factor: 5.156

10.  Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Authors:  A Finckh; A Ciurea; L Brulhart; B Möller; U A Walker; D Courvoisier; D Kyburz; J Dudler; C Gabay
Journal:  Ann Rheum Dis       Date:  2009-05-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.